Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: neuroscience – Page 897

Summary: Researchers say coffee prevents Alzheimer’s and Parkinson’s for those consuming 3 cups daily. The brain health benefits of the beverage seem to differ between decaf and regular coffee. [Author: Brady Hartman. This article first appeared on LongevityFacts.com.]

Perhaps you’ve heard the latest news – the evidence on coffee’s health benefits is increasing every day.

In fact, new research shows that coffee protects your brain, and recent studies show that daily coffee drinkers have a significantly reduced risk of both Alzheimer’s and Parkinson’s diseases.

Read more

“Yes, Mr. Bedford is here.”

That’s what Marji Klima, executive assistant at the Alcor Life Extension Foundation in Scottsdale, Arizona, told me over email this week. She was referring to Dr. James Hiram Bedford, a former University of California-Berkeley psychology professor who died of renal cancer on Jan. 12, 1967. Bedford was the first human to be cryonically preserved—that is, frozen and stored indefinitely in the hopes that technology to revive him will one day exist. He’s been at Alcor since 1991.

His was the first of 300 bodies and brains currently preserved in the world’s three known commercial cryonics facilities: Alcor; the Cryonics Institute in Clinton Township, Michigan; and KrioRus near Moscow. Another 3,000 people still living have arranged to join them upon what cryonicists call “deanimation.” In other words, death.

Read more

For anyone who has accidentally injured themselves, Dr. Zachary Campbell not only sympathizes, he’s developing new ways to blunt pain.

“If you have ever hit yourself with a hammer, afterward, even a light touch can be painful for days or even weeks,” said Campbell, who researches pain on the molecular level at The University of Texas at Dallas. “While many of us may not be coordinated enough to avoid an accident, my goal is to disrupt the inception and persistence of pain memories.”

Campbell directs the Laboratory of RNA Control and recently published a study in the journal Nature Communications in close collaboration with Dr. Ted Price, an associate professor from the Pain Neurobiology Research Group, and Dr. Michael Burton, a new assistant professor from the School of Behavioral and Brain Sciences who conducted postdoctoral work at UT Dallas.

Read more

Distinct amyloid-beta prion strains discovered in different variants of Alzheimer’s disease.

In a paper in the Proceedings of the National Academy of Sciences, a research team led by Carlo Condello presented their results from a study of the sliced brain fragments of deceased Alzheimer’s disease (AD) patients. It appears different amyloid-beta prions are uniquely associated with different AD variants [1].

A primer on Alzheimer’s disease

AD is a chronic neurodegenerative disease affecting about 5% of the population above 65 years of age—the time when the first symptoms usually manifest. It is estimated to be the cause of up to 70% of all cases of dementia, which according to WHO projections, by 2050 will be around 115 million.

Continue reading “Distinct Types of Amyloid-beta Prion Strains in Alzheimer’s Disease Discovered” | >

Scientists are searching for an effective Parkinsons treatment.

Summary: A disease-modifying drug for Parkinson’s disease remains the goal of researchers as they develop promising treatments using gene therapy, autophagy upregulators, and brain mapping. [Author: Brady Hartman. This article first appeared on LongevityFacts.]

Parkinson’s, Alzheimer’s and other forms of dementia are diseases of aging, and the incidence of these conditions rise with each passing year. Doctors expect these disorders to ramp up with increasing life expectancies.

Researchers aren’t just focusing on treatments for Alzheimer’s disease. Fortunately, scientists throughout the world are developing promising treatments for Parkinson’s disease as well.

Continue reading “Chasing Breakthrough Cures for Parkinson’s Disease” | >

The famed startup incubator Y Combinator put out a call for companies that want to increase human longevity and “health span.”

Who they want: Founders with new ideas for treating old-age diseases like Alzheimer’s, “but we will also consider more radical anti-aging schemes,” YC president Sam Altman told MIT Technology Review.

Why longevity? Efforts to stop old age don’t actually get funded much. “My sense is that economic incentives of drugs companies are screwed up” says Altman. “I don’t think we have enough people saying, How can we make a lot of people a lot heathier?”

Read more